PriceTargets.com logo

Revelation Biosciences - REVB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.35 As of 01/22/2025 05:00 PM ET
▼ -0.0646 (-15.65%)

This chart shows the closing price for REVB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revelation Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REVB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Revelation Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.35.

This chart shows the closing price for REVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Revelation Biosciences. This rating has held steady since January 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/14/2023Roth MkmBoost TargetBuy$150.00 ➝ $450.00
2/17/2022Roth CapitalInitiated CoverageBuy$12,600.00
(Data available from 1/23/2020 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/27/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2025

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Revelation Biosciences logo
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
Read More

Today's Range

Now: $0.35
Low: $0.34
High: $0.40

50 Day Range

MA: $0.53
Low: $0.29
High: $0.95

52 Week Range

Now: $0.35
Low: $0.28
High: $25.26

Volume

915,885 shs

Average Volume

9,188,476 shs

Market Capitalization

$1.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Revelation Biosciences?

The following equities research analysts have issued stock ratings on Revelation Biosciences in the last year:
View the latest analyst ratings for REVB.

What is the current price target for Revelation Biosciences?

0 Wall Street analysts have set twelve-month price targets for Revelation Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Revelation Biosciences in the next year.
View the latest price targets for REVB.

What is the current consensus analyst rating for Revelation Biosciences?

Revelation Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for REVB.

What other companies compete with Revelation Biosciences?

Other companies that are similar to Revelation Biosciences include Viracta Therapeutics, Orgenesis, Evoke Pharma, GRI Bio and Alzamend Neuro. Learn More about companies similar to Revelation Biosciences.

How do I contact Revelation Biosciences' investor relations team?

The company's listed phone number is 650-800-3717 and its investor relations email address is [email protected]. The official website for Revelation Biosciences is www.revbiosciences.com. Learn More about contacing Revelation Biosciences investor relations.